N-(2-azabicyclo[2.2.1]hept-5-yl)-furo[2,3-b]pyridine-2-carboxamide | 508208-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: N-(2-azabicyclo[2.2.1]hept-5-yl)-furo[2,3-b]pyridine-2-carboxamide
• 英文别名: N-(2-azabicyclo[2.2.1]heptan-5-yl)furo[2,3-b]pyridine-2-carboxamide
• CAS: 508208-30-8
• 化学式: C₁₄H₁₅N₃O₂
• 分子量: 257.292
• InChiKey: HTEXJTURMFKNDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
  申请人：——

  公开号：US20030153595A1

  公开（公告）日：2003-08-14

  The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 3 These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.

  该发明提供了Formula I中的化合物：1其中Azabicyclo为23这些化合物可以是药用盐或组合物的形式，或者是它们的外消旋混合物或纯对映体。Formula I中的化合物在已知涉及α7的药物中是有用的。
• Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
  申请人：Walker Patrick Daniel

  公开号：US20050234092A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

  本发明提供了I式化合物：其中Azabicyclo为这些化合物可以是药物盐或组合物，外消旋混合物或其纯对映体。式I的化合物在已知α7参与的制药领域中是有用的。
• AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1432707B1

  公开（公告）日：2012-03-28
• US6911543B2
  申请人：——

  公开号：US6911543B2

  公开（公告）日：2005-06-28
• [EN] AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE<br/>[FR] COMPOSES D'HETEORARYLE FUSIONNE SUBSTITUES PAR AZABICYCLO UTILES POUR LE TRAITEMENT DE MALADIES
  申请人：UPJOHN CO

  公开号：WO2003029252A1

  公开（公告）日：2003-04-10

  The invention provides compounds of Formula (I), wherein Azabicyclo is formulas (II-VII), W is formulas (VIII-X). These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.